Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142886 | 0.94 | TAAR1 (0.53) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL141983 | 0.92 | TAAR1 (0.52) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL11577289 | 0.92 | TAAR1 (0.52) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL144121 | 0.88 | — | — | |
| SCHEMBL20135772 | 0.80 | TAAR1 (0.73) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL20146704 | 0.80 | TAAR1 (0.73) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL10722210 | 0.80 | TAAR1 (0.55) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL10652123 | 0.80 | TAAR1 (0.55) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL8571535 | 0.78 | TAAR1 (0.70) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL6734915 | 0.78 | TAAR1 (0.70) | TAAR1TSHRSMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666866-B2 | Antithrombotic diamides | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | claimed |
| EP-1819693-B1 | ANTITHROMBOTIC DIAMIDES | LILLY CO ELI (US) | 2009-08-26 | — | — | EP | claimed |
| US-20090062271-A1 | Antithrombotic Diamides | ELI LILLY AND COMPANY (US) | 2009-03-05 | — | — | US | claimed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | claimed |
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | disclosed |
| US-20240034845-A1 | POLYMER PARTICLES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-01 | — | — | US | disclosed |
| EP-3384549-B1 | SODIUM-ION ELECTROLYTE COMPOSITION | UNIV DEAKIN (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | disclosed |
| US-20230348674-A1 | HYDROGELS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2023190111-A1 | RAFT POLYMERIZATION REACTION SOLUTION AND RAFT POLYMERIZATION REACTION SOLUTION PRODUCTION METHOD | テクノＵＭＧ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| CN-113939544-B | non-core-shell polymer particles | 悉尼大学 | 2023-08-22 | — | — | CN | disclosed |
| US-4643987-A | VANCOMYCINS | ELI LILLY AND COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
| US-4497738-A | Analogous compounds of cephalosporins, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-02-05 | — | — | US | disclosed |
| US-4472300-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| EP-0017138-B1 | ANALOGOUS COMPOUNDS OF CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-04 | — | — | EP | disclosed |
| EP-0070575-A2 | New starting compounds for preparing analogous compounds of cephalosporins and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-01-26 | — | — | EP | disclosed |
| US-4339449-A | Analogous compounds of cephalosporins, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1982-07-13 | — | — | US | disclosed |
| EP-0017138-A2 | Analogous compounds of cephalosporins, processes for their preparation, and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-10-15 | — | — | EP | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062271-A1 | Antithrombotic Diamides | TFPI, SERPINC1, TFPI2 | TAAR1 4153/4885TSHR 1985/4885SMN1; SMN2 3805/4885 |
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | TAAR1 3576/4885TSHR 2551/4885SMN1; SMN2 3971/4885 |
| US-20230348674-A1 | HYDROGELS | PHYKPL, TST, PHOSPHO1 | TAAR1 2105/4885TSHR 1684/4885SMN1; SMN2 4773/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | TAAR1 3576/4885TSHR 2551/4885SMN1; SMN2 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.